Poll: what price will bluebird bio close on Monday??
Bluebird bio (Nasdaq: BLUE) released important new data from their HGB-205 study at the European Hematology Association's 20th Congress in Vienna, Austria today. In this study, which is being conducted in France, bluebird is trying to use its gene therapy technology to fix two serious hemoglobinopathies: beta-thalassemia major and sickle cell disease.
For beta-thalassemia major, bluebird reported a follow-up on two patients. They have now been transfusion-independent for 14 and 16 months, respectively.
For sickle cell disease, bluebird reported new data on their first ever patient (they published preliminary data in an abstract on May 21st). This patient has now been transfusion free for more than three months, and the amount of anti-sickling hemoglobin now makes up 45% of all of his hemoglobin production.
You can read more about the news and its significance in Adam Feuerstein's excellent recap here.
If you follow biotech, you already know that bluebird has been an amazing stock. In fact, the market capitalization has climbed to over $6 billion before this weekend's news. So I thought it would be interesting to test the wisdom of the crowd and play a guessing game before Monday's open....where do you think bluebird will close on Monday given this weekend's data??
UPDATE: Voting is now closed and the results are in. Thanks to all of those who participated!
Click chart to expand
Who Am I?
I'm an individual investor from Kansas City. My focus is on biotech stocks, but I enjoy investing in all industries. I'm an old-school, buy and hold investor who believes the best way to outperform and grow capital is to own innovative companies with good management teams over the long-term. more>>